Workflow
Q2 Metals Reports Multiple Wide, Mineralized Intercepts at the Cisco Lithium Project, Including 272.5 Metres at 1.61% Li20
Globenewswire· 2025-09-29 11:00
Highlights: Three (3) drill holes from the 2025 drill program with strong analytical results are reported herein: CS25-036: nine (9) separate intervals, the widest being 272.5 m at 1.61% Li2O. CS25-038: 17 separate intervals, the widest being 66.5 m at 1.55% Li2O and 58.9 m at 1.09% Li2O. CS25-039: 12 separate intervals, including: 108.5 m at 1.62% Li2O,71.0 m at 1.84% Li2O, 77.7 m at 1.48% Li2O, and107.4 m at 1.87% Li2O Three (3) drill rigs continue to operate on the Cisco Project, with a fourth schedul ...
Brunswick Exploration Discovers Additional Spodumene Pegmatites in Paamiut, Greenland
Globenewswire· 2025-09-29 11:00
MONTREAL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce that it has confirmed a historical spodumene pegmatite and discovered a second one at its Paamiut project in Greenland. Brunswick Exploration now has two projects with confirmed lithium showings in Greenland and is the only company actively looking for lithium in Greenland. Mr. Killian Charles, President and CEO of BRW, commented: “Following the exp ...
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
Globenewswire· 2025-09-29 11:00
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chi ...
Barrick Announces Leadership Transition
Globenewswire· 2025-09-29 11:00
Mark Hill Appointed Group COO and Interim President & CEO Search Underway to Identify Successor President & CEO All amounts expressed in U.S. dollars TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has appointed Mark Hill as Group COO and Interim President and Chief Executive Officer, effective immediately, following the departure of Mark Bristow. Mark Hill, who is curren ...
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Globenewswire· 2025-09-29 11:00
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4 key clinica ...
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Globenewswire· 2025-09-29 11:00
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval Magnesium-potentiated intranasal oxytocin formulation designed to reduce dose-related inconsistencies in receptor activity CHATHAM, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Toni ...
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Globenewswire· 2025-09-29 11:00
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and dosing interval data anticipated mid-year 2026 Company to host R&D Spotlight Webcast today, September 29, 2025 WELLESLEY HILLS, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, ...
K Wave Media Announces Plans to Launch One of the First Entertainment Tokenization Platforms with Strategic Investment from Galaxy Digital and Backing from Korea’s Leading IP Companies
Globenewswire· 2025-09-29 11:00
NEW YORK and SEOUL, South Korea, Sept. 29, 2025 (GLOBE NEWSWIRE) -- K Wave Media (Nasdaq: KWM), a Korean cultural innovation and digital asset company, today announced plans to develop one of the industry’s first entertainment tokenization platforms. The platform will offer innovative tools such as revenue-sharing tokens that enable fractional ownership in films, concerts, branded content, and IP rights, along with smart contract–based automated royalty distribution to ensure transparent payouts to creators ...
Lithium Ionic Closes First Tranche of Oversubscribed $15M Non-brokered Private Placement
Globenewswire· 2025-09-29 11:00
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lithium Ionic Corp. (TSXV: LTH; OTCQB: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) reports that is has closed the first tranche of its previously announced non-brokered private placement financing of 18,350,141 units (the “Units”) at $0.70 per Unit for gross proceeds of $12,845,09 ...
NOVONIX Achieves Critical Operational Milestone
Globenewswire· 2025-09-29 10:54
Commercial-grade sample First mass production, industrial-grade sample of synthetic graphite. NOVONIX Riverside Facility NOVONIX's Riverside facility in Chattanooga, Tennessee, poised to become the first large-scale production site dedicated to high-performance synthetic graphite for the battery, defense, and industrial sectors in North America. CHATTANOOGA, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and ...